https://www.livescience.com/health/cancer/crispr-used-to-reprogram-cancer-cells-into-healthy-muscle-in-the-lab Skip to main content (*) ( ) Open menu Close menu Live Science [ ] Search Search Live Science [ ] Subscribe RSS How It Works Magazine How It Works Magazine Why subscribe? * The ultimate action-packed science and technology magazine bursting with exciting information about the universe * Subscribe today and save an extra 5% with checkout code 'LOVE5' * Engaging articles, amazing illustrations & exclusive interviews * Issues delivered straight to your door or device From$3.99 View * * Space * Health * Planet Earth * Animals * Archaeology * Physics & Math * Human Behavior * Technology * Chemistry * More + Science news + About Us + Forum + Story archive Trending * Mysterious 'golden orb' * Hottest summer on record * Whale strandings * India lunar lander * iPads deals When you purchase through links on our site, we may earn an affiliate commission. Here's how it works. 1. Health 2. Viruses, Infections & Disease 3. Cancer CRISPR used to 'reprogram' cancer cells into healthy muscle in the lab News By Emily Cooke published 5 September 2023 In a new study, stopping skeletal-muscle cancer cells from making a specific protein forced them to turn into healthy muscle cells. * * * * * * * Comments (0) spindle-shape muscle cells shown depicted in bright green and blue against a black background The transformed tumor cells lost all of their cancer-like traits and instead resembled normal muscle cells, donning a spindle-like shape, as seen here. (Image credit: Vakoc lab/Cold Spring Harbor Laboratory) Scientists have transformed cancer cells into healthy muscle tissue in the lab using CRISPR gene-editing technology -- and they hope new cancer treatments can be built on the back of this experiment. In a study published Aug. 28 in the journal PNAS, researchers found that disabling a particular protein complex in cells of rhabdomyosarcoma (RMS) -- a rare cancer in skeletal muscle tissue that mainly affects children under age 10 -- in the laboratory causes the tumor cells to turn into healthy muscle cells. Although the research is still in its early days, this process of "resetting" cancer cells into healthy cells, broadly known as differentiation therapy, has already been tested in other types of cancer, such as bone and blood cancer. Four drugs have been approved by the U.S. Food and Drug Administration (FDA) to treat the latter disease and generally work by inhibiting a specific protein in the cancer cells. The protein complex pinpointed in the new research could serve as a target for such a therapy, the study authors wrote, and with further development, it could be a promising new treatment option for patients with RMS, which is normally treated with surgery, radiation and chemotherapy. "This technology can allow you to take any cancer and go hunting for how to cause it to differentiate," or cause it to stop multiplying uncontrollably and turn into normal, noncancerous cells, Christopher Vakoc, lead author and professor at Cold Spring Harbor Laboratory, said in a statement. "This might be a key step toward making differentiation therapy more accessible." Related: Meet 'Fanzor,' the 1st CRISPR-like system found in complex life Differentiation is a process in which stem cells divide and form the various types of cells in the body, such as muscle or fat cells, which each have a unique pattern of gene expression that enables them to carry out particular functions. In RMS, however, patients have genetic mutations that cause their cells to make a specific protein, called PAX3-FOXO1, which stops differentiation from happening in skeletal muscle cells. So instead of turning into muscle, the cells form a mass of cancerous tissue. In the new study, the researchers used CRISPR to disable, or "knock out," different genes to see which ones make proteins that work together with PAX3-FOXO1 to stop RMS cells from differentiating. Their analysis revealed that, if RMS cells lose the ability to make nuclear factor Y (NF-Y) -- a protein that regulates gene expression -- the cells instead differentiate into muscle cells. Knocking out PAX3-FOXO1 directly has the same effect. "The tumor loses all cancer attributes," Vakoc said in the statement. "They're switching from a cell that just wants to make more of itself to cells devoted to contraction." RELATED STORIES --A teen's cancer is in remission after she received new cells edited with CRISPR --CRISPR stops coronavirus replication in human cells --Doctors are trying to use CRISPR to fight cancer. The 1st trial suggests it's safe Although deactivating PAX3-FOXO1 and NF-Y has similar effects, the researchers discovered that the proteins don't physically interact with each other. Instead, in RMS cells, NF-Y switches on the genes needed to make PAX3-FOXO1 by binding to a specific sequence of DNA. So by blocking NF-Y, the researchers also blocked production of PAX3-FOXO1. The findings are still a long way from being translated into a treatment for RMS. However, drugs that inhibit NF-Y are already being developed, including those that stop the protein complex from forming or binding to DNA. One hurdle that will need to be overcome is that NF-Y also regulates important processes in healthy cells, such as metabolism and the cell cycle, the series of steps that cells go through as they grow and divide. However, Vakoc and team hypothesize that because RMS cells are "highly sensitive" to changes in PAX3-FOXO1 expression, there could be a "window of opportunity" in which a drug inhibits NF-Y long enough for RMS cells to differentiate but not so long that healthy tissues get damaged. More research will be needed to confirm that this is a viable treatment strategy, they wrote. Live Science newsletter Stay up to date on the latest science news by signing up for our Essentials newsletter. [ ][ ]Contact me with news and offers from other Future brands[ ]Receive email from us on behalf of our trusted partners or sponsors[Sign me up] By submitting your information you agree to the Terms & Conditions and Privacy Policy and are aged 16 or over. Emily Cooke Emily Cooke Social Links Navigation Staff Writer Emily is a health news writer based in London, United Kingdom. She holds a bachelor's degree in biology from Durham University and a master's degree in clinical and therapeutic neuroscience from Oxford University. She has worked in science communication, medical writing and as a local news reporter while undertaking journalism training. In 2018, she was named one of MHP Communications' 30 journalists to watch under 30. (emily.cooke@futurenet.com) More about cancer tightly coiled DNA shown in orange wrapped around a large blue protein, called a histone DNA's 'topography' influences where cancer-causing mutations appear illustrated light red cancer cells being attacked by blue immune cells. an x chromosome can be seen in a cancer cell on the left side, which has no immune cells on it, while more immune cells are on another cancer cell to the right, which has both an x and a y chromosome 'Disappearing' Y chromosome in aging men may worsen bladder cancer, mouse study shows Latest A moose and bear showdown caught on night vision camera. Watch bear and wolf attack moose mom and calf at same time in rare, remarkable footage See more latest > TOPICS CRISPR See all comments (0) [ ] No comments yet Comment from the forums Most Popular [missing-im]Lost 'rainbow cup' coin minted by Celts 2,000 years ago discovered in Germany By Laura GeggelSeptember 08, 2023 [missing-im]Blood clot risk linked to taking common painkillers alongside certain hormonal birth control By Emily CookeSeptember 08, 2023 [missing-im]'It is biological in origin': 1st analysis of weird golden orb from ocean floor leaves scientists stumped By Hannah OsborneSeptember 08, 2023 [missing-im]Move over, python -- this tiny snake holds the record for swallowing the largest prey whole relative to body size By Jennifer NalewickiSeptember 08, 2023 [missing-im]Most advanced lab-made human embryo models look like the real thing By Nicoletta LaneseSeptember 07, 2023 [missing-im]India's lunar lander finds 1st evidence of a moonquake in decades By Ben TurnerSeptember 07, 2023 [missing-im]Origins of enslaved Africans freed by British, then abandoned on remote Atlantic island revealed by DNA analysis By Ben TurnerSeptember 07, 2023 [missing-im]For the 1st time, scientists accidentally measure the swirling ring around a black hole By Harry BakerSeptember 07, 2023 [missing-im]Could an impending rise in solar storms cause more whales to strand? By Harry BakerSeptember 07, 2023 [missing-im]This was the hottest summer ever recorded on Earth By Aimee GabaySeptember 07, 2023 [missing-im]DNA's 'topography' influences where cancer-causing mutations appear By Rebecca SohnSeptember 07, 2023 MOST READMOST SHARED 1. A human skeleton surrounded by artifacts. 1 Bronze Age girl buried with more than 150 animal ankle bones, potentially to help her to the next world 2. 2 Move over, python -- this tiny snake holds the record for swallowing the largest prey whole relative to body size 3. 3 How many planets are in the universe? 4. 4 Scientists finally figure out why cats are obsessed with tuna 5. 5 Centuries-old technique reveals hidden '3D' animals in Paleolithic cave art 1. An ancient Egyptian clay vessel depicting a human. 1 Elite ancient Egyptian woman was embalmed with exotic ingredients smelling of vanilla and larch, new analysis reveals 2. 2 'Twisty' new theory of gravity says information can escape black holes after all 3. 3 Photographer captures rare 'gigantic jets' of upside-down lightning blasting out of Atlantic hurricane 4. 4 James Webb telescope reveals the universe may have far fewer active black holes than we thought 5. 5 NASA's OSIRIS-REx mission almost bit the dust -- then Queen guitarist Brian May stepped in Live Science is part of Future US Inc, an international media group and leading digital publisher. Visit our corporate site. * About Us * Contact Future's experts * Terms and conditions * Privacy policy * Cookies policy * Accessibility Statement * Advertise with us * Web notifications * Careers (c) Future US, Inc. Full 7th Floor, 130 West 42nd Street, New York, NY 10036.